Ankrd65, an intriguing protein at the crossroads of cellular stress responses and differentiation, holds pivotal significance in orchestrating various cellular processes. Functionally, Ankrd65 operates as a multifaceted scaffold protein, intricately involved in mediating interactions between chromatin and the transcriptional machinery. Positioned as a key player in transcriptional regulation, Ankrd65 exerts its influence on gene expression patterns, thereby wielding substantial control over cell fate decisions and responses to external stimuli. The protein's involvement in cellular processes extends to its role as a modulator of chromatin structure and accessibility, contributing to the orchestration of gene expression programs. As a scaffold, Ankrd65 facilitates the assembly of transcriptional complexes, serving as a molecular bridge between chromatin regions and the transcriptional machinery. This architectural role positions Ankrd65 as a crucial determinant of gene expression, impacting cellular differentiation, stress responses, and adaptation to environmental cues. Moreover, Ankrd65 has been implicated in the regulation of various signaling pathways, further underscoring its significance in coordinating cellular activities.
Inhibition of Ankrd65 involves a strategic interference with the intricate signaling pathways associated with its regulatory functions. This inhibition primarily occurs through the modulation of key cellular cascades, such as the TGF-β, PI3K/AKT, JNK, and MAPK/ERK pathways. The presented inhibitors act indirectly on Ankrd65 by disrupting these pathways, altering the phosphorylation status of critical signaling molecules, and subsequently influencing downstream cellular responses. For instance, inhibition of TGF-β signaling, achieved by compounds like SB-431542, leads to an indirect suppression of Ankrd65 expression. Similarly, targeting the PI3K/AKT pathway, as exemplified by LY294002, results in modified AKT-dependent processes that indirectly impact Ankrd65. These indirect mechanisms of inhibition highlight the intricate web of cellular processes that converge on Ankrd65, emphasizing its role as a central orchestrator of transcriptional regulation. The presented inhibitors provide valuable tools for researchers to dissect the complex interplay between Ankrd65 and the signaling pathways that govern its function. As our understanding of these regulatory networks deepens, new avenues for manipulating Ankrd65 expression may emerge, shedding light on the nuanced dynamics of cellular responses to stress and differentiation.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor inhibitor that impedes TGF-β signaling cascades by blocking receptor phosphorylation. Alters downstream signaling, indirectly suppressing Ankrd65 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor hindering the PI3K/AKT pathway. Modulates intracellular signaling cascades affecting Ankrd65 indirectly through altered AKT-dependent processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
JNK inhibitor influencing the JNK signaling pathway. Indirectly impacts Ankrd65 expression by altering the activation of JNK-mediated transcriptional processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor disrupting PI3K-dependent signaling. Alters intracellular pathways indirectly affecting Ankrd65 expression through modulation of AKT-mediated processes. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
Inhibitor of histone methyltransferase EZH2, influencing epigenetic regulation. Alters chromatin structure and indirectly impacts Ankrd65 expression by modifying transcriptional accessibility. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
IKK inhibitor impeding NF-κB signaling. Indirectly suppresses Ankrd65 expression by preventing NF-κB-mediated transcriptional activation and subsequent involvement in cellular responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor affecting mTORC1 signaling. Modulates protein translation and indirectly influences Ankrd65 expression through altered translation of proteins involved in its regulatory pathways. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $108.00 $162.00 $234.00 $924.00 | 45 | |
ERK inhibitor affecting the MAPK pathway. Indirectly influences Ankrd65 expression by altering the phosphorylation status of ERK and subsequently modifying downstream cellular responses. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
Dual mTORC1 and mTORC2 inhibitor. Indirectly affects Ankrd65 expression by disrupting mTOR signaling cascades and modulating processes related to protein synthesis and cellular homeostasis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor influencing the MAPK pathway. Alters Ankrd65 expression indirectly by modifying the activation of ERK and subsequently impacting downstream cellular responses. |